{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:41:07Z","timestamp":1787312467275,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.det.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:41:05Z","timestamp":1562719265000},"page":"409-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Systemic Therapies for Advanced Melanoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Leonora","family":"Bomar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Senithilnathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib1","first-page":"6","article-title":"Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAFV600E-Specific Inhibitor)","volume":"24","author":"Torres-Collado","year":"2018","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.det.2019.05.001_bib2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-Mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.det.2019.05.001_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-018-1167-7","article-title":"Generalizability of clinical trials of advanced melanoma in the real-world, population-based settings","volume":"35","author":"Sam","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.det.2019.05.001_bib4","first-page":"2135","article-title":"Improved survival with vemurafenib in melanoma","volume":"353","author":"Chapman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib5","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomized phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.det.2019.05.001_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","article-title":"Treatments for metastatic melanoma: Synthesis of evidence from randomized trials","volume":"33","author":"Lui","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.det.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008390-199510000-00010","article-title":"Dacarbazine, cisplatin, carmustine, with or without tamoxifen, for metastatic melanoma: a 5-year follow-up","volume":"5","author":"Lattanzi","year":"1995","journal-title":"Melanoma Res"},{"key":"10.1016\/j.det.2019.05.001_bib9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2019.05.001_bib10","first-page":"2","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"6","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.det.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00002371-200107000-00004","article-title":"Guidelines for safe administration of high-dose interleukin-2","volume":"24","author":"Schwartzentruber","year":"2001","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.det.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF 600E-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.det.2019.05.001_bib14","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"354","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib15","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.det.2019.05.001_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2019.05.001_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomized controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jdv.15363","article-title":"The spectrum of cutaneous adverse events during Encorafenib and Binimetinib treatment in BRAF mutant advanced melanoma","volume":"33","author":"Graf","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquired resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.det.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to BRAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.det.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers RAF inhibitor resistance to melanoma cells through suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.det.2019.05.001_bib22","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-13-0827","article-title":"Tumor genetic analyses of patients with metastatic melanoma treated with BRAF inhibitor dabrafenib","volume":"19","author":"Nathanson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villaneuva","year":"2010","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.det.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.det.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1200\/jco.2010.28.15_suppl.8592","article-title":"PLX4032(RG7204), a selective mutant RAF inhibitor: Clinical and histological characteristics of therapy-associated cutaneous neoplasms in a phase I trial","volume":"28","author":"Lacouture","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: Practical advice on diagnosis, prevention, and management of main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2019.05.001_bib27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib(GSk2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.001_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies","volume":"72","author":"Macdonald","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.det.2019.05.001_bib29","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/DSS.0000000000000519","article-title":"Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer","volume":"42","author":"Tang","year":"2016","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib30","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","article-title":"Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma","volume":"71","author":"Sanlorenzo","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.001_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"Ras mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2019.05.001_bib32","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","article-title":"Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib","volume":"30","author":"Anforth","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","article-title":"Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma","volume":"148","author":"Alloo","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.001_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjd.12659","article-title":"Clearance of BRAF inhibitor-associated keratoacanthomas by systemic retinoids","volume":"170","author":"Sachse","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamadermatol.2013.2583","article-title":"A\u00a0novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil","volume":"149","author":"LaPresto","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000439272","article-title":"Early-onset vemurafenib-induced DRESS syndrome","volume":"232","author":"Munch","year":"2016","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.14201","article-title":"Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds","volume":"174","author":"Bellon","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.det.2019.05.001_bib40","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.13039","article-title":"Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature","volume":"29","author":"Mossner","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2019.05.001_bib41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2019.05.001_bib42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2019.05.001_bib43","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib44","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/1346-8138.14200","article-title":"Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma","volume":"45","author":"Fusumae","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.det.2019.05.001_bib45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","article-title":"Vemurafenib and radiosensitization","volume":"149","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib46","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/bjd.15259","article-title":"Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event","volume":"176","author":"Herms","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib47","first-page":"766","article-title":"Vitiligo of the face in a patient treated with vemurafenib for metastatic melanoma","volume":"15","author":"Nasca","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib48","first-page":"305","article-title":"Vemurafenib-induced granuloma annulare","volume":"14","author":"Lee","year":"2016","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib49","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/DAD.0000000000000281","article-title":"BRAF inhibitor-induced antitumoral granulomatous dermatitis eruption in advanced melanoma","volume":"37","author":"Garrdio","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation","volume":"231","author":"Lheure","year":"2015","journal-title":"Dermatology"},{"issue":"suppl 1","key":"10.1016\/j.det.2019.05.001_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1590\/abd1806-4841.20153841","article-title":"Vemurafenib and cutaneous adverse events-report of five cases","volume":"90","author":"Silva Gde","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib52","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald","year":"2015","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000487128","article-title":"Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma","volume":"11","author":"De Haan","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"11","key":"10.1016\/j.det.2019.05.001_bib54","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2012.45.2870","article-title":"Treatment of metastatic malignant melanoma with vemurafenib during pregnancy","volume":"31","author":"Maleka","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.det.2019.05.001_bib56","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12788\/j.sder.0061","article-title":"Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab","volume":"33","author":"Choi","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"26","key":"10.1016\/j.det.2019.05.001_bib59","first-page":"2507","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"364","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effect of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"20","key":"10.1016\/j.det.2019.05.001_bib61","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2019.05.001_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.det.2019.05.001_bib63","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib65","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double blind, phase III trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib67","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10105","key":"10.1016\/j.det.2019.05.001_bib69","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.det.2019.05.001_bib70","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (Checkmate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.det.2019.05.001_bib71","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib72","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2019.05.001_bib74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: Inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib75","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2019.05.001_bib76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2017-0015","article-title":"Management of the cutaneous adverse effects of antimelanoma therapy","volume":"4","author":"Liu","year":"2017","journal-title":"Melanoma Manag"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/09546634.2013.813897","article-title":"Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2","volume":"25","author":"Ma","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.det.2019.05.001_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib79","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","article-title":"Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab","volume":"69","author":"Reule","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib80","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib81","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/CMR.0000000000000477","article-title":"Nivolumab induced inflammation of seborrheic keratosis: a novel cutaneous manifestation in a metastatic melanoma patient","volume":"28","author":"Rambhia","year":"2018","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib82","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A\u00a0review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2019.05.001_bib83","doi-asserted-by":"crossref","DOI":"10.5070\/D3239036484","article-title":"Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab","volume":"23","author":"Sundaresan","year":"2017","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib84","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/cup.13133","article-title":"Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer","volume":"45","author":"Diaz-Perez","year":"2018","journal-title":"J\u00a0Cutan Pathol"},{"issue":"12","key":"10.1016\/j.det.2019.05.001_bib85","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/cup.13044","article-title":"Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy-Report of 2 patients","volume":"44","author":"Tetzlaff","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"issue":"8","key":"10.1016\/j.det.2019.05.001_bib86","first-page":"307","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J\u00a0Immunother"},{"issue":"5","key":"10.1016\/j.det.2019.05.001_bib87","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2019.05.001_bib88","doi-asserted-by":"crossref","first-page":"900a","DOI":"10.1200\/jco.2014.32.15_suppl.9008a","article-title":"Primary overall survival from OPTIM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB\/C and IV melanoma","volume":"32","author":"Kaufman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.det.2019.05.001_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/cancers10100356","article-title":"The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic and breast cancers","volume":"10","author":"Elissa","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"25","key":"10.1016\/j.det.2019.05.001_bib90","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.det.2019.05.001_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"9","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-017-0458-3","article-title":"The use of immunotherapy in the treatment of melanoma","volume":"10","author":"Achkar","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"10.1016\/j.det.2019.05.001_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2019.05.001_bib94","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2019.05.001_bib95","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the Gm2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2019.05.001_bib96","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon-a2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863519300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:44:04Z","timestamp":1760006644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863519300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0733863519300439"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2019.05.001","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapies for Advanced Melanoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}